T
Thomas Martin
Researcher at University of California, San Francisco
Publications - 311
Citations - 17918
Thomas Martin is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Exocytosis. The author has an hindex of 73, co-authored 242 publications receiving 15771 citations. Previous affiliations of Thomas Martin include Institut national de la recherche agronomique & University of Western Australia.
Papers
More filters
Journal ArticleDOI
Evidence for the Role of Calcium and Diacylglycerol as Dual Second Messengers in Thyrotropin-Releasing Hormone Action: Involvement of Diacylglycerol*
TL;DR: The ability of TRH to rapidly stimulate PRL secretion (phase I) is correlated with its ability to rapidly promote a transient cytoplasmic Ca-2 concentration rise from an intracellular Ca+2 pool.
Journal ArticleDOI
Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
Paul G. Richardson,Jeff Wolf,Andrzej Jakubowiak,Jeff Zonder,Sagar Lonial,David Irwin,John J. Densmore,Amrita Krishnan,Noopur Raje,Michael Bar,Thomas Martin,Robert L. Schlossman,Irene M. Ghobrial,Nikhil C. Munshi,Jacob P. Laubach,Jeff Allerton,Teru Hideshima,Kathleen Colson,Enrique Poradosu,L. Gardner,Peter Sportelli,Kenneth C. Anderson +21 more
TL;DR: Clinical data suggest that perifosine in combination with dexamethasone has activity in relapsed or relapsed/refractory multiple myeloma, and a phase III trial is underway comparing perifOSine-bortezomib plus dexamETHasone with bortzomib-dexameth asone in patients with relapsed / refractory MM previously treated with bortsomib.
Journal ArticleDOI
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma
Michael Wang,Thomas Martin,William I. Bensinger,Melissa Alsina,David S. Siegel,Edward Kavalerchik,Mei Huang,Robert Z. Orlowski,Ruben Niesvizky +8 more
TL;DR: CRd at the MPD was well tolerated with robust, rapid, and durable responses, and overall response rate (ORR) was 76.9% with median time to response of 0.95 month.
Journal ArticleDOI
Specific Binding of Phosphatidylinositol 4,5-Bisphosphate to Calcium-dependent Activator Protein for Secretion (CAPS), a Potential Phosphoinositide Effector Protein for Regulated Exocytosis
TL;DR: CAPS, as a novel neural/endocrine-specific cytosolic and peripheral membrane protein required for the Ca2+-regulated exocytosis of secretory vesicles, may function in regulated exocyTosis as an effector of PtdIns(4,5)P2.